Madrigal Pharmaceuticals (MDGL) Stock: Price, Trend, Options & Financials
Madrigal Pharmaceuticals's price regime, relative strength, unusual-options and unusual-volume history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
MDGL closed at $516.74 on Aug 21, 2026. The price is -1.2% from its 50-day average and +0.6% from its 200-day average, which places it in the rules-based “split trend” regime. The relative-strength check: over three months the stock returned +0.6%, trailing SPY by 2.5%. It remains 16.0% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is -1.2% from its 50-day average and +0.6% from its 200-day average. Over three months, MDGL returned +0.6% versus +3.1% for SPY.
- vs 50-day
- -1.2%
- vs 200-day
- +0.6%
- From 52W high
- -16.0%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
MDGL appeared in a UOA top-30 list on 0 of 62 archived scanner sessions: 0 call-side, 0 put-side and 0 on both lists. The latest session did not place it in either top 30. No eligible current chain row was available, so the page does not manufacture a latest composite score.
| Recent flag | Call rank | Put rank |
|---|---|---|
| No issuer-level top-30 flags in the current archive. | ||
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. The current scanner did not supply an eligible row for this issuer.
Curated-manager ownership
2 of the 20 managers in the project's curated 13F set reported a long Madrigal Pharmaceuticals position in their latest filing, worth $722M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Paulson & Co John Paulson · MDGL | $720M | 27.94% | 1.34M | -3.8% reduced | 2026-06-30 |
Baron Capital Group Ron Baron · MDGL | $2M | 0.00% | 4,500 | -15.1% reduced | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open MDGL Financials →How MDGL trades — the working manual
Madrigal commercializes Rezdiffra, the first approved therapy for non-cirrhotic NASH with moderate to advanced fibrosis, and is effectively a single-product company in its launch phase. For the stock, prescription growth, reimbursement and the cash required to fund the launch matter more than any single quarter's reported loss.
What can move the tape
- 01Prescription trends, patient starts, adherence and the shape of the launch curve.
- 02Payer coverage, prior-authorization friction and net price realization.
- 03Diagnosis and referral rates for NASH, which gate the addressable patient pool.
- 04Commercial spending, cash runway and the timing of profitability.
What can fool the read
- 01Revenue is concentrated in one product, so a launch disappointment has no offset elsewhere.
- 02Reimbursement and prior-authorization requirements can separate prescriptions from recognized revenue.
- 03Competing therapies in late-stage development could change the market before the launch matures.
- 04The company is still loss-making, so financing needs can dilute holders if the launch slows.
No MDGL flags in the committed 2026-04-01–2026-08-21 archive. That means no session cleared this project's anomaly threshold; it does not mean trading volume was literally constant.
Not published yet. The local archive has 1 reported MDGL events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-23 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
MDGL stock questions
Is MDGL stock in an uptrend?+
MDGL is classified in the “split trend” regime as of 2026-08-21: the close is -1.2% from its 50-day average and +0.6% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in MDGL mean?+
MDGL has not appeared in either issuer-level top-30 list during the current archive. A future flag would identify an OTM chain outlier relative to the scanner universe. It would identify no buyer, seller, institution or spread leg.
Are the MDGL 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are MDGL's income statement and cash flow?+
The dedicated MDGL Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no MDGL earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.